---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-129488"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2024-11-21T23:59:59+00:00"
generated_at: "2026-05-29T20:57:14.452486+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Korro Bio receives Australian clearance to begin Phase 1/2a study of KRRO-110 for Alpha-1 Antitrypsin Deficiency

## Summary
- Australian HREC approval and TGA clearance obtained for Phase 1/2a REWRITE study of KRRO-110 in AATD.
- First participant dosing expected Q1 2025; interim readout H2 2025; study completion anticipated 2026.
- KRRO-110 aims to edit RNA to produce functional M-AAT; in mouse model, >60% editing achieved at therapeutically relevant levels.
- Study will evaluate safety, tolerability, PK/PD of single and multiple ascending doses in PiZZ genotype patients.

## SEC filing metadata
- accession: 0000950170-24-129488
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2024-11-21T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000095017024129488/0000950170-24-129488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000095017024129488/krro-20241121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-129488
- JSON: https://secwatch.observer/filing/0000950170-24-129488.json
- Plain text: https://secwatch.observer/filing/0000950170-24-129488.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.